Skip to content
Oct 25, 2021
Anticancer Bioscience: A Precision Therapeutics Company Dedicated to Discovering and Developing Breakthrough Cancer Therapies for Unmet Oncology Needs Around the World
Sept 4, 2021
Treating Cancer with Novel Synthetic Lethal Therapies
July 23, 2021
Mini-library Approach Delivers an Arsenal in Drug Development Pipeline
July 14, 2021
Anticancer Bioscience appoints Dr. Hong Liu, as US-based VP of clinical development
July 14, 2021
ACB hires Liu from Eureka Therapeutics to lead push into clinic
June 14, 2021
Anticancer Bioscience: applying synthetic lethality to MYC-driven cancers
June 7, 2021
Dun Yang – President & CEO, Anticancer Bioscience
March 25, 2021
Synthetic lethal drugs vs. cancer
February 9, 2021
Anticancer Bioscience Raises $10M to Advance Synthetic Lethality Programs
February 9, 2021
China’s Anticancer Bioscience raises $10 million, aims high in China
February 8, 2021
Anticancer Bioscience announces $10 million financing
February 08, 2021
A synthetic lethality player emerges in China, armed with lessons on undruggable oncogene from Nobel laureate's lab
